WILYY:OTO-William Demant Holding A/S ADR (USD)

COMMON STOCK | Medical Devices | OTC Pink

Last Closing

USD 22.2

Change

0.00 (0.00)%

Market Cap

USD 5.26B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

William Demant Holding A/S develops, manufactures and sells products and equipment designed to aid the hearing and communication of individuals.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
SEMHF Siemens Healthineers AG

N/A

USD 63.37B
SMMNY Siemens Healthineers AG ADR

-0.31 (-1.09%)

USD 63.37B
RYLPF Koninklijke Philips N.V

-0.68 (-2.52%)

USD 18.28B
SONVY Sonova Holding AG

+0.82 (+1.41%)

USD 16.80B
SONVF Sonova Holding AG

+4.28 (+1.52%)

USD 16.20B
CHEOF Cochlear Limited

+8.00 (+3.85%)

USD 13.75B
CHEOY CochLear Ltd ADR

+0.77 (+0.71%)

USD 13.71B
WILLF Demant A/S

N/A

USD 11.14B
SNNUF Smith & Nephew plc

-0.22 (-1.74%)

USD 10.71B
GNGBF Getinge AB

N/A

USD 5.73B

ETFs Containing WILYY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.64% 66% D+ 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.64% 66% D+ 56% F
Trailing 12 Months  
Capital Gain 4.91% 75% C 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.91% 75% C 65% D
Trailing 5 Years  
Capital Gain 47.02% 79% B- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 47.02% 78% C+ 78% C+
Average Annual (5 Year Horizon)  
Capital Gain 17.32% 63% D 64% D
Dividend Return 17.32% 63% D 60% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 43.84% 71% C- 55% F
Risk Adjusted Return 39.50% 87% B+ 77% C+
Market Capitalization 5.26B 93% A 90% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.